Osborne Clarke advises naturalX Health Ventures on investment in Jutro Medical

Osborne Clarke has advised consumer health investor naturalX Health Ventures on its investment in Polish healthtech company Jutro Medical as part of an extension of its Series A funding round. The round was led by Warsaw Equity Group; in addition to naturalX Health Ventures, participants included Vinci, Fluent Ventures, Aternus, KAYA VC and Inovo VC. The financing also includes a debt component provided by mBank and Orbit Capital. In total, the Series A funding volume has increased to EUR 36 million.

Jutro Medical, headquartered in Warsaw, is an “AI‑first” primary care provider that combines digital and physical care in an integrated model. Since it was founded in 2020 by Adam Janczewski, the company has developed its own electronic health records (EHR) system, standardised clinic processes and AI‑based tools, which in particular support documentation and patient intake.

The company is pursuing a roll‑up strategy in the field of general practice: Jutro Medical acquires existing practices and integrates them into a unified operating and technology platform with a shared EHR system, standardised workflows and AI support. According to the company, Jutro Medical has added nine further clinics to its network this year alone and aims to acquire around 20 practices per year. The company currently provides care to around 120,000 patients in Poland and plans to roll out its model to other European markets in the future.

“Jutro Medical is strengthening exactly where healthcare begins for most people: primary care. The company is not only improving access, but also raising the quality of care through better coordination, technology-enabled workflows and a clear focus on prevention,” said Marvin Amberg, Managing Director of naturalX Health Ventures. “The combination of operational excellence, a scalable M&A roll-up strategy and the thoughtful use of AI to reduce administrative burden on medical teams makes Jutro one of the most compelling primary care platforms emerging in Europe. We are excited to support Adam Janczewski and his team as they continue to scale this model in Poland and expand into additional European markets.”

The Osborne Clarke team, led by Till‑Manuel Saur, which advised naturalX Health Ventures, comprised Robert Marx (both Corporate / VC), Dr Ulrike Bär and Florian Berlejung (both Tax) (all Osborne Clarke Germany), as well as Rafal Kozlowski, (Corporate / VC), Dr Agnieszka Sztoldman, Piotr Plachecki (both IP), Adam Strzelecki (Commercial), Szymon Tyniec (VC) and Sławomir Kowalski (Data Protection) (all Osborne Clarke Poland).